Abstract
Treatment with 200 to 400 mg/day fluconazole was evaluated in 44 patients without AIDS who had cryptococcosis (19 with cryptococcal meningitis, 22 with pulmonary cryptococcosis, 3 with other cryptococcal infections). For all patients, the clinical response rate was 89% (48% were clinically cured and 41 % clinically improved). Of the patients with cryptococcal meningitis, 89% were mycologically cured. These rates are comparable to those obtained in the treatment of AIDS patients with cryptococcal disease. In the group of patients with cryptococcal meningitis, there was a high rate of agreement between the mycological response to therapy and cryptococcal antigen test results. The use of cryptococcal antigen testing is recommended in all patients with cryptococcosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Armstrong DP: Treatment of opportunistic fungal infections. Clinical Infectious Diseases 1993, 16: 1–9.
Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, Leonard J, Fields BT, Bradshaw M, Haywood H, McGee ZA, Cate TR, Cobbs CG, Warner JF, Alling DW: A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. New England Journal of Medicine 1979, 301: 126–131.
Dismukes WE, Cloud G, Gallis HA, Kerkering TM, Medoff G, Draven PC, Kaplowitz LG, Fisher JF, Gregg CR, Bowles CA, Shadomy S, Stamm AM, Diasio RB, Kaufman L, Soong S, Blackwelder WC: Treatment of cryptococcal meningitis with combination of amphotericin B and flucytosine for four as compared with six weeks. New England Journal of Medicine 1987, 317: 3334–3341.
Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GA, Bowles CA, Karam GH: Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. American Journal of Medicine 1987, 83: 236–242.
Dismukes WE: Cryptococcal meningitis in patients with AIDS. Journal of Infectious Diseases 1988, 157: 624–628.
Stern JJ, Hartman BJ, Sharkley P, Rowland V, Squires KE, Murray HW, Graybill JR: Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. American Journal of Medicine 1988, 85: 477–480.
Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco H, Sharkey PK, Thompson SE, Sugar AM, Tuazon CU, Fisher JF, Hyslop N, Jacobson JM, Hafener R, Dismukes WE: Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. New England Journal of Medicine 1992, 326: 83–89.
Yagamuchi H: Chemotherapy of cryptococcal meningitis and other forms of cryptococcosis: recent developments and trends. Journal of the Asian Medical Association Southeast Asia 1994, 10, Supplement: 217–219.
Debruyne D, Ryckelynck JP: Clinical pharmacokinetics of fluconazole. Clinical Pharmacokinetics 1993, 24: 10–27.
Lim SG, Sawyer AM, Hudson M, Sercombe J, Pounder RE: The absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Alimentary Pharmacology and Therapy 1993, 7: 317–321.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yamaguchi, H., Ikemoto, H., Watanabe, K. et al. Fluconazole monotherapy for cryptococcosis in non-AIDS patients. Eur. J. Clin. Microbiol. Infect. Dis. 15, 787–792 (1996). https://doi.org/10.1007/BF01701520
Issue Date:
DOI: https://doi.org/10.1007/BF01701520